Investigational Drug Abaloparatide-sc Can Help Postmenopausal Women with Osteoporosis

Video

Abaloparatide-sc can benefit postmenopausal women with osteoporosis by helping increase greater bone mineral density, since building bone strength is important for these women's health.

At the ACR/ARHP meeting, Lori Fitzpatrick, MD, explained that abaloparatide-sc can benefit postmenopausal women with osteoporosis by helping increase greater bone mineral density, since building bone strength is important for these women's health. There's also less hypercalcemia, a common side effect with other similar drugs. Fitzpatrick shared, "The approval date with the FDA is the 30th of March of next year, so we're hopeful we will be approved by the regulatory agency and hopefully be able to bring the drug to patients."

Related Videos
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Building a Psoriasis Knockout Regimen Around Risankizumab, with Andrew Blauvelt, MD, MBA
Joel Gelfand, MD, MSCE: Phototherapy Utility in Psoriasis
Pediatric Hidradenitis Suppurativa Severity not Linked to Obesity
© 2024 MJH Life Sciences

All rights reserved.